AVEO Pharmaceuticals (NASDAQ:AVEO) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday, January 9th.
AVEO has been the subject of several other research reports. Zacks Investment Research downgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 6th. Seaport Global Securities reaffirmed a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Friday, October 6th. B. Riley assumed coverage on shares of AVEO Pharmaceuticals in a research note on Monday, November 13th. They set a “buy” rating and a $5.00 price target for the company. Finally, assumed coverage on shares of AVEO Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $5.00 price target for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. AVEO Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.05.
Shares of AVEO Pharmaceuticals (NASDAQ AVEO) traded down $0.09 during midday trading on Tuesday, reaching $2.99. 2,000,000 shares of the company’s stock traded hands, compared to its average volume of 1,693,270. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of -0.32. AVEO Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $4.24. The company has a market capitalization of $353.78, a P/E ratio of -4.21 and a beta of 1.30.
AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.03. The company had revenue of $4.61 million for the quarter, compared to the consensus estimate of $6.50 million. research analysts predict that AVEO Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at $164,000. Fore Research & Management LP purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at $111,000. Rehmann Capital Advisory Group purchased a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at $193,000. OxFORD Asset Management LLP purchased a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at $228,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at $550,000. 50.94% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “BidaskClub Downgrades AVEO Pharmaceuticals (NASDAQ:AVEO) to Strong Sell” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/04/bidaskclub-downgrades-aveo-pharmaceuticals-aveo-to-strong-sell.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.